Anti-tumor Drug Market (Updated Version Available)

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
In China, antitumor drugs are also the key areas of concern for many enterprises. Such as Jiangsu Hengrui, Qilu Pharmaceutical and other well-known domestic enterprises in the anti-tumor drugs have invested a lot of money, there are many innovative anti-cancer drugs into the clinical research stage. In the meantime, there has been explosive growth in the development of molecularly targeted drugs, with at least hundreds of drugs under development, and it is conceivable that the market will be quite crowded in the next five to 10 years. Therefore, domestic enterprises should fully understand the feasibility of the project and the fierce market competition that they may face in the future.
China's bio-pharmaceutical industry already has a good foundation; from the national level to local governments at all levels continue to step up efforts to support the development of bio-pharmaceutical industry. The output value of the pharmaceutical industry maintained a growth rate of 20% during the 12th Five-Year Plan period. In 2013, the total output value of the pharmaceutical industry reached 2.1 trillion yuan. However, compared with the bio-pharmaceutical industry in the advanced countries in the world, there is still a huge gap between the biomedical industry in our country and the demand for building an overall well-to-do society. Mainly manifested in: small-scale enterprises, more than 10 billion yuan enterprises and more than one billion yuan less; independent innovation ability is weak, many varieties of imitation with independent intellectual property rights of the few species; restrict some of the long-term development of biomedical industry , Deep-seated problems still exist.

The report offers detailed coverage of Anti-tumor Drug industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Anti-tumor Drug by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

The report forecast global Anti-tumor Drug market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2027.

First, this report covers the present status and the future prospects of the global Anti-tumor Drug market for 2015-2027.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

Key Companies
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka

At the same time, we classify Anti-tumor Drug according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Market Segment as follows:
Market by Order Type
Cytotoxic Drugs
Non-cytotoxic Drugs
Market by Application
Alkylating Agents
Anti-metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline antitumor drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs

By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Anti-tumor Drug market for the forecast period 2021 - 2027?
• What are the driving forces in the Anti-tumor Drug market for the forecast period 2021 - 2027?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Anti-tumor Drug industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?